{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:14:27Z","timestamp":1779297267845,"version":"3.51.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Case Coulter Translational Research Partnership"},{"name":"Clinical and Translational Science Collaborative"},{"name":"John Patrick Carey Foundation for Pediatric Research Metrohealth Medical System"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Systemic lupus erythematosus (SLE) is driven by abnormal type-I and -II interferon activation, affecting a variety of immunocompetent cells. Mesenchymal stromal cells (MSCs) can modulate inflammation but often lack consistent potency. We developed HXB-319, an MSC-based therapy targeting inflammatory pathways in SLE. Previously, HXB-319 was shown to reduce alveolar hemorrhage in an SLE model. Here, we report its effects in a model of SLE that progresses to end stage kidney disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>SLE-like disease was induced via intraperitoneal (IP) pristane injection in female BALB\/cJ mice, followed by treatment with na\u00efve MSCs or HXB-319. Over 9 months, survival and proteinuria were monitored. Upon euthanasia, kidneys were analyzed for histopathology and gene expression, splenocytes for immune subsets by flow cytometry, and serum for autoantibodies, growth factors, and cytokines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HXB-319 significantly altered plasmacytoid dendritic cells, CD4+PD-L1+ cells, and both CD4+ and CD8+ ROR\u03b3t+ (Th17 cells) subsets. HXB-310 lowered IFN-\u03b3 (P\u2005&amp;lt;\u20050.001), IL-17A (P\u2005=\u20050.01), BAFF (P\u2005&amp;lt;\u20050.05), and anti-dsDNA (P\u2005&amp;lt;\u20050.05), compared to untreated mice. HXB-319, but not na\u00efve MSCs, significantly improved survival, halted progression of kidney disease, and stabilized proteinuria (all P\u2005&amp;lt;\u20050.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>HXB-319 demonstrates potential for mitigating SLE-associated glomerulonephritis, improving survival, and reducing proteinuria and glomerulosclerosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/stmcls\/sxaf040","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T21:56:22Z","timestamp":1751320582000},"source":"Crossref","is-referenced-by-count":2,"title":["A novel trained mesenchymal stromal cell-based therapy, HXB-319, effectively controls progressive glomerulonephritis in a murine lupus model"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2256-9068","authenticated-orcid":false,"given":"Hulya","family":"Bukulmez","sequence":"first","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, Metrohealth Medical Center, Case Western Reserve University , Cleveland, 44109, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne T","family":"Dennis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, Metrohealth Medical Center, Case Western Reserve University , Cleveland, 44109, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Reese-Koc","sequence":"additional","affiliation":[{"name":"Cellular Therapy Operations and Quality, National Center for Regenerative Medicine, School of Medicine, Case Western Reserve University , Cleveland, 44106, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kleinsorge-Block","sequence":"additional","affiliation":[{"name":"Cellular Therapy Operations and Quality, National Center for Regenerative Medicine, School of Medicine, Case Western Reserve University , Cleveland, 44106, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Sieg","sequence":"additional","affiliation":[{"name":"Immunology Flow Core, Department of Medicine, Division of Infectious Diseases and HIV Medicine, Case Western Reserve University , Cleveland, 44106, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin B","family":"Highland","sequence":"additional","affiliation":[{"name":"Department of Pulmonary\/Critical Care, Rheumatic Lung Disease Program, Cleveland Clinic Foundation, Case Western Reserve University , Cleveland, 44106, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven N","family":"Emancipator","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Case Western Reserve University , Cleveland, 44106, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025082204065458500_CIT0001","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"2025082204065458500_CIT0002","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med."},{"key":"2025082204065458500_CIT0003","doi-asserted-by":"publisher","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","author":"Morand","year":"2023","journal-title":"BMJ"},{"key":"2025082204065458500_CIT0004","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet."},{"key":"2025082204065458500_CIT0005","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41581-023-00722-z","article-title":"Pathogenic cellular and molecular mediators in lupus nephritis","volume":"19","author":"Mohan","year":"2023","journal-title":"Nat Rev Nephrol."},{"key":"2025082204065458500_CIT0006","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/keaa379","article-title":"Classifying and diagnosing systemic lupus erythematosus in the 21st century","volume":"59","author":"Aringer","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025082204065458500_CIT0007","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erythematosus for new therapies","volume":"27","author":"Allen","year":"2021","journal-title":"Trends Mol Med."},{"key":"2025082204065458500_CIT0008","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet","year":"2022","journal-title":"Kidney Int."},{"key":"2025082204065458500_CIT0009","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","article-title":"Lupus nephritis: clinical presentations and outcomes in the 21st century","volume":"59","author":"Gasparotto","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025082204065458500_CIT0010","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol."},{"key":"2025082204065458500_CIT0011","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/MNH.0000000000000969","article-title":"New guidelines and therapeutic updates for the management of lupus nephritis","volume":"33","author":"Desai","year":"2024","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"2025082204065458500_CIT0012","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"2025082204065458500_CIT0013","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol."},{"key":"2025082204065458500_CIT0014","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.placenta.2009.12.006","article-title":"Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche","volume":"31","author":"Castrechini","year":"2010","journal-title":"Placenta."},{"key":"2025082204065458500_CIT0015","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA."},{"key":"2025082204065458500_CIT0016","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.3390\/ijms25168981","article-title":"Lupus nephritis from pathogenesis to new therapies: an update","volume":"25","author":"Roveta","year":"2024","journal-title":"Int J Mol Sci ."},{"key":"2025082204065458500_CIT0017","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nrrheum.2010.80","article-title":"Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE","volume":"6","author":"Liang","year":"2010","journal-title":"Nat Rev Rheumatol."},{"key":"2025082204065458500_CIT0018","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41467-019-10491-8","article-title":"Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients","volume":"10","author":"Yuan","year":"2019","journal-title":"Nat Commun."},{"key":"2025082204065458500_CIT0019","doi-asserted-by":"publisher","first-page":"e116061","DOI":"10.1371\/journal.pone.0116061","article-title":"Demineralized bone matrix combined bone marrow mesenchymal stem cells, bone morphogenetic protein-2 and transforming growth factor-beta3 gene promoted pig cartilage defect repair","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One."},{"key":"2025082204065458500_CIT0020","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000513741","article-title":"An update for mesenchymal stem cell therapy in lupus nephritis","volume":"7","author":"Li","year":"2021","journal-title":"Kidney Dis (Basel)"},{"key":"2025082204065458500_CIT0021","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"2025082204065458500_CIT0022","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2018.05.034","article-title":"Mesenchymal stem cells control complement C5 activation by factor h in lupus nephritis","volume":"32","author":"Ma","year":"2018","journal-title":"EBioMedicine"},{"issue":"2","key":"2025082204065458500_CIT0023","doi-asserted-by":"publisher","first-page":"sxae078","DOI":"10.1093\/stmcls\/sxae078","article-title":"Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model","volume":"43","author":"Bukulmez","year":"2024","journal-title":"Stem Cells."},{"key":"2025082204065458500_CIT0024","author":"Bukulmez","year":"2023"},{"key":"2025082204065458500_CIT0025","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ecco-jcc\/jjac172","article-title":"A phase IB\/IIA study of allogeneic, bone marrow-derived, mesenchymal stem cells for the treatment of refractory ileal-anal anastomosis and peripouch fistulas in the setting of crohn\u2019s disease of the pouch","volume":"17","author":"Lightner","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025082204065458500_CIT0026","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/08830185.2020.1742712","article-title":"Contribution of mouse models in our understanding of lupus","volume":"39","author":"Halkom","year":"2020","journal-title":"Int Rev Immunol."},{"key":"2025082204065458500_CIT0027","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s10067-017-3811-6","article-title":"Pristane-induced lupus: considerations on this experimental model","volume":"36","author":"Freitas","year":"2017","journal-title":"Clin Rheumatol."},{"key":"2025082204065458500_CIT0028","doi-asserted-by":"publisher","first-page":"i88","DOI":"10.1093\/rheumatology\/kew400","article-title":"Modelling clinical systemic lupus erythematosus: similarities, differences and success stories","volume":"56","author":"Celhar","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025082204065458500_CIT0029","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1746-6148-9-123","article-title":"Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review","volume":"9","author":"Klopfleisch","year":"2013","journal-title":"BMC Vet Res."},{"key":"2025082204065458500_CIT0030","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ki.1990.309","article-title":"Platelet activating factor receptor blockade ameliorates murine systemic lupus erythematosus","volume":"38","author":"Baldi","year":"1990","journal-title":"Kidney Int."},{"key":"2025082204065458500_CIT0031","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1745-6150-7-3","article-title":"IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL\/lpr mice","volume":"7","author":"Greenspan","year":"2012","journal-title":"Biol Direct"},{"key":"2025082204065458500_CIT0032","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","article-title":"Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus","volume":"62","author":"Sun","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2025082204065458500_CIT0033","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3727\/096368911X582769c","article-title":"Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience","volume":"22","author":"Wang","year":"2013","journal-title":"Cell Transplant."},{"key":"2025082204065458500_CIT0034","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"2025082204065458500_CIT0035","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"2025082204065458500_CIT0036","first-page":"1018","article-title":"[Immunoregulatory effect of bone marrow mesenchymal stem cells on regulatory T cells in patients with systemic lupus erythematosis]","volume":"46","author":"Sun","year":"2007","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2025082204065458500_CIT0037","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","article-title":"A long-term follow-up study of allogeneic mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus","volume":"10","author":"Wang","year":"2018","journal-title":"Stem Cell Rep."},{"key":"2025082204065458500_CIT0038","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.transproceed.2009.06.119","article-title":"Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function","volume":"41","author":"Renner","year":"2009","journal-title":"Transplant Proc."},{"key":"2025082204065458500_CIT0039","doi-asserted-by":"publisher","first-page":"1473788","DOI":"10.3389\/fimmu.2025.1473788","article-title":"Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity","volume":"16","author":"Valencia","year":"2025","journal-title":"Front Immunol."}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stmcls\/advance-article-pdf\/doi\/10.1093\/stmcls\/sxaf040\/63630175\/sxaf040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/43\/9\/sxaf040\/63630175\/sxaf040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/43\/9\/sxaf040\/63630175\/sxaf040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:07:06Z","timestamp":1755850026000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/doi\/10.1093\/stmcls\/sxaf040\/8178846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/stmcls\/sxaf040","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,1]]},"article-number":"sxaf040"}}